CB2 receptor ligands for the treatment of psychiatric disorders
View Patent ↗The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4′-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome.
1. A method for the treatment of a psychiatric disorder selected from the group consisting of Attention Deficit Hyperactivity Disorder (ADHD)/Attention Deficit Disorder (ADD), hyperactivity, a tic disorder, and a combination thereof, the method comprising administering to a subject in need of such treatment a pharmaceutical composition comprising a CB2 receptor inverse agonist of formula I:
or a salt thereof and a pharmaceutically acceptable carrier,
wherein R 1 and R 2 are each independently selected from the group consisting of hydrogen, C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, C 1 -C 8 haloalkyl, or C 3 -C 8 cyclohaloalkyl, and
wherein R 1 and R 2 are not both hydrogen.
2. The method according to claim 1 , wherein R 1 is hydrogen and R 2 is methyl, and the CB2 receptor inverse agonist is 4′-O-Methylhonokiol.
3. The method according to claim 1 , wherein the psychiatric disorder is ADHD.
4. The method according to claim 1 , wherein the tic disorder is Tourette's syndrome.
5. The method according to claim 1 , wherein the CB2 receptor inverse agonist is 4′-O-Methylhonokiol and the psychiatric disorder is ADHD.
6. The method according to claim 1 , wherein the CB2 receptor inverse agonist is 4′-O-Methylhonokiol and the psychiatric disorder is Tourette's syndrome.
7. The method according to claim 1 , wherein the pharmaceutical composition is formulated as a solution, suspension, emulsion, powder, tablet, capsule, depot, transdermal patch, spray, and suppository.
8. The method according to claim 1 , wherein the pharmaceutical composition is administered to the subject in need thereof by a route selected from the group consisting of oral, intravenous, intramuscular, intraperitoneal, subcutaneous, inhalation, transdermal, vaginal, and rectal administration route.
9. A method for treating a psychiatric disorder comprising administering to a subject in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of a CB2 receptor inverse agonist and a pharmaceutically acceptable carrier, wherein the CB2 receptor inverse agonist is a selective estrogen receptor modulator (SERM), and wherein the psychiatric disorder is selected from the group consisting of Attention Deficit Hyperactivity Disorder (ADHD)/Attention Deficit Disorder (ADD), hyperactivity, obsessive compulsive disorder (OCD), and a combination thereof.
10. The method according to claim 9 , wherein the SERM is selected from the group consisting of raloxifene, bazedoxifene, lasofoxifene, tamoxifen, afimoxifene, arzoxifene, ormeloxifene, toremifene, ospemifene, and a combination thereof.
11. The method according to claim 9 , wherein the SERM is selected from the group consisting of raloxifene, bazedoxifene, lasofoxifene and tamoxifen.
12. The method according to claim 9 , wherein the psychiatric disorder is ADHD.
13. The method according to claim 9 , wherein the SERM is raloxifene and the psychiatric disorder is ADHD.
14. The method according to claim 9 , wherein the pharmaceutical composition is formulated as a solution, suspension, emulsion, powder, tablet, capsule, depot, transdermal patch, spray, and suppository.
15. The method according to claim 9 , wherein the pharmaceutical composition is administered to the subject in need thereof by a route selected from the group consisting of oral, intravenous, intramuscular, intraperitoneal, subcutaneous, inhalation, transdermal, vaginal, and rectal administration route.